Skip to main content
    V

    VistaGen Therapeutics Inc (VTGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.18
    +0.00 (+2.11%)

    Market Cap: $8.01M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    VistaGen Therapeutics Inc (VTGN) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    VistaGen Therapeutics (VTGN) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, VistaGen Therapeutics reported EPS of -$0.24, above the -$0.37 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -19.36%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.37
    Range-$0.37 - -$0.36
    2 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.370.0%
    60d ago-$0.370.0%
    30d ago-$0.36-1.4%
    7d ago-$0.36-1.4%
    Current-$0.37
    Revenue Consensus
    $250.00K
    RangeN/A
    2 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.37
    RangeN/A
    4 analysts
    Revenue Consensus
    $255.00K
    RangeN/A
    4 analysts

    Next Report

    VTGN has an expected report date of Feb 10, 2027.

    VTGN Earnings Call

    The latest VTGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, VTGN beat 21, missed 18 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $138000, down 46.5% from $258000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.24-$0.37-$0.38 - -$0.37+35.14%BeatN/A20 up, 2 downNov 13, 2026$138000
    Jun 30, 2026-$0.30-$0.29N/A-3.45%MissN/A20 up, 1 downAug 14, 2026$1.48M
    Mar 31, 2026-$0.37-$0.42N/A+11.90%BeatN/A32 up, 1 downJun 15, 2026$464000
    Dec 31, 2025-$0.45-$0.48-$0.54 - -$0.42+6.25%BeatN/A40 up, 3 downFeb 12, 2026$303000
    Sep 30, 2025-$0.54-$0.44-$0.49 - -$0.35-22.73%MissN/A30 up, 1 downNov 13, 2025$258000
    Jun 30, 2025-$0.47-$0.47-$0.47 - -$0.470.00%In lineN/A10 up, 1 downAug 7, 2025$244000
    Mar 31, 2025-$0.44-$0.85N/A+48.24%BeatN/A21 up, 0 downJun 17, 2025N/A
    Dec 31, 2024-$0.46-$0.52-$0.54 - -$0.50+11.54%BeatN/A20 up, 1 downFeb 13, 2025$234000
    Sep 30, 2024-$0.42-$0.39-$0.41 - -$0.37-7.69%MissN/A40 up, 0 downNov 7, 2024$183000
    Jun 30, 2024-$0.35-$0.40-$0.41 - -$0.40+12.50%BeatN/A20 up, 0 downAug 13, 2024$84000
    Mar 31, 2024-$0.25-$0.36-$0.46 - -$0.27+30.56%BeatN/A40 up, 0 downJun 11, 2024$198000
    Dec 31, 2023-$0.22-$0.27-$0.39 - -$0.27+18.52%BeatN/A40 up, 0 downFeb 13, 2024$411000
    Sep 30, 2023-$0.66-$0.68-$0.68 - -$0.68+2.94%BeatN/A10 up, 0 downNov 9, 2023$278000
    Jun 30, 2023-$0.94-$0.86N/A-9.30%MissN/AN/A0 up, 0 downAug 10, 2023$177000
    Mar 31, 2023-$1.75-$1.50-$1.50 - -$1.50-16.67%MissN/A10 up, 0 downJun 22, 2023$175600
    Dec 31, 2022-$1.50-$1.80-$2.40 - -$1.80+16.67%BeatN/A20 up, 0 downFeb 7, 2023$179600
    Sep 30, 2022-$2.40-$0.60-$3.00 - -$0.60-300.00%MissN/A30 up, 0 downNov 10, 2022N/A
    Jun 30, 2022-$3.00-$2.25-$2.40 - -$2.10-33.33%MissN/A20 up, 1 downAug 11, 2022$310100
    Mar 31, 2022-$0.09-$0.06-$0.06 - -$0.05-50.00%MissN/A40 up, 0 downJun 23, 2022$1.33M
    Dec 31, 2021-$1.50-$2.25-$2.40 - -$2.10+33.33%BeatN/A4N/AFeb 10, 2022$179600
    Sep 30, 2021-$2.10-$2.25-$2.70 - -$1.20+6.67%BeatN/A4N/ANov 10, 2021$358000
    Jun 30, 2021-$1.20-$1.80N/A+33.33%BeatN/A3N/AAug 12, 2021$354100
    Mar 31, 2021-$0.20-$0.05-$0.06 - -$0.04-300.00%MissN/A4N/AJun 29, 2021$87800
    Dec 31, 2020-$2.10-$1.60-$1.80 - -$1.50-31.25%MissN/A3N/AFeb 11, 2021$313600
    Sep 30, 2020-$1.50-$0.70-$1.50 - $0.60-114.29%MissN/A3N/ANov 12, 2020$334000
    Jun 30, 2020-$2.10-$3.00-$4.50 - -$3.00+30.00%BeatN/A2N/AAug 13, 2020$354100
    Mar 31, 2020-$0.07-$0.08-$0.10 - -$0.06+12.50%BeatN/A2N/AJun 29, 2020N/A
    Dec 31, 2019-$4.50-$2.10-$2.10 - -$2.10-114.29%MissN/A1N/AFeb 13, 2020N/A
    Sep 30, 2019-$3.90-$4.05-$4.50 - -$3.60+3.70%BeatN/A2N/ANov 7, 2019N/A
    Jun 30, 2019-$4.50-$3.30-$3.30 - -$3.30-36.36%MissN/A1N/AAug 16, 2019N/A
    Mar 31, 2019-$0.17-$0.12-$0.12 - -$0.12-41.67%MissN/A1N/AJun 25, 2019N/A
    Dec 31, 2018-$7.20-$6.45-$9.01 - -$3.90-11.63%MissN/A2N/AFeb 12, 2019N/A
    Sep 30, 2018-$9.00-$5.10-$5.71 - -$4.50-76.47%MissN/A2N/AOct 29, 2018N/A
    Jun 30, 2018-$6.00-$4.20-$4.20 - -$4.20-42.86%MissN/A1N/AAug 14, 2018N/A
    Mar 31, 2018-$0.09-$0.41N/A+78.05%BeatN/A1N/AJun 26, 2018N/A
    Dec 31, 2017-$7.50-$8.10N/A+7.41%BeatN/A1N/AFeb 12, 2018N/A
    Sep 30, 2017-$0.53-$0.38N/A-39.47%MissN/AN/AN/ANov 9, 2017N/A
    Jun 30, 2017-$8.40-$12.30N/A+31.71%BeatN/AN/AN/AAug 14, 2017N/A
    Mar 31, 2017-$0.31-$0.50N/A+38.00%BeatN/AN/AN/AJun 29, 2017$1.25M
    Dec 31, 2016-$10.20-$11.10N/A+8.11%BeatN/AN/AN/AFeb 13, 2017$1.25M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Mar 31, 2026 was -$1.83, after -$1.67 the year before. It was -$38.41 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Mar 31, 2026-$1.83N/A
    Mar 31, 2025-$1.67N/A
    Mar 31, 2024-$2.07N/A
    Mar 31, 2023-$8.65N/A
    Mar 31, 2022-$4.89N/A
    Mar 31, 2021-$5.90N/A
    Mar 31, 2020-$12.97N/A
    Mar 31, 2019-$22.37N/A
    Mar 31, 2018-$16.52N/A
    Mar 31, 2017-$38.41N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,900 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,9159
    2026Q2Jun 30, 20262,9468
    2026Q1Mar 31, 20263,5749
    2025Q4Dec 31, 20253,4747
    2025Q3Sep 30, 20253,8849
    2025Q2Jun 30, 20253,7869
    2025Q1Mar 31, 20253,1009
    2024Q4Dec 31, 20244,0147

    2026Q3 Earnings Call

    Opening remarks

    Mark McPartland Senior Vice President, Investor Relations Thank you, Lisa, and good afternoon, everyone, and welcome to our conference call and webcast. Earlier this afternoon, we filed our quarterly report on Form 10-Q and issued a press release for our fiscal year 2026 third quarter, which ended December 31, 2025, and provided an update of our progress across our clinical stage neuroscience program. We encourage you to review the press release and 10-Q which are both available in the Investors section of our website. Before we begin, please note that we'll be making forward-looking statements regarding our business during today's call based on current expectations and information. These forward-looking statements speak only as of today. Except as law requires, we do not assume any duty to update any forward-looking statements made today or in the future. Of course, forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements we make today. Additional information concerning risks and factors that could affect our business and our financial results are included in our fiscal year 2026 third quarter Form 10-Q for the period ending December 31, 2025, and in future filings that we make with the SEC from time to time. Again, all of which are available in the Investors section of our website or on the SEC's website. With the formalities completed, we warmly welcome our stockholders, sell-side analysts and others interested in our programs in progress. I'm joined on our call today by Shawn Singh, our President and Chief Executive Officer; Joshua Prince, our Chief Operating Officer; and Nick Tressler, our Chief Financial Officer. Shawn will provide a brief business and clinical update, and Josh and Nick will be available to provide additional feedback during the Q&A portion of our call. After our remarks, we'll take questions from the sell-side analysts participating on the call. A replay of the webcast will be available in the Events section of the Investor page of our website. With that taken care of, I'd now like to turn the call over to our President and CEO, Shawn Singh.

    Shawn Singh President and Chief Executive Officer Thank you, Mark, and good afternoon, everyone. It's been an important quarter for our team with the completion of the randomized portion of our PALISADE-3 Phase III trial in social anxiety disorder, as guided, and focused efforts to learn from the study's results and drive high-quality and efficient execution of our ongoing PALISADE-4 Phase III trial. We have reviewed available data from PALISADE-3 and implemented moderate refinements, including retraining, site rationalization and operational enhancements to PALISADE-4.

    Frequently Asked Questions About VTGN

    When is VistaGen Therapeutics's next earnings date?

    VistaGen Therapeutics's next earnings report is expected for Feb 10, 2027.

    Did VTGN beat earnings estimates last quarter?

    Yes. VistaGen Therapeutics reported EPS of -$0.24 for the quarter ended Sep 30, 2026, above the -$0.37 estimate, a 35.14% surprise.

    What EPS do analysts expect from VTGN next quarter?

    The consensus EPS estimate for VistaGen Therapeutics for the quarter ending Dec 31, 2026 is -$0.37 from 2 analysts, with estimates from -$0.37 to -$0.36.

    How often does VTGN beat earnings estimates?

    VistaGen Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +10.86%.